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Background: Cohort studies provide an excellent opportunity to monitor changes in behaviour and disease
transmission over time. In Australia, cohort studies of people who inject drugs (PWID) have generally focused on
older, in-treatment injectors, with only limited outcome measure data collected. In this study we specifically sought
to recruit a sample of younger, largely out-of-treatment PWID, in order to study the trajectories of their drug use
over time.
Methods: Respondent driven sampling, traditional snowball sampling and street outreach methods were used to
recruit heroin and amphetamine injectors from one outer-urban and two inner-urban regions of Melbourne,
Australia. Information was collected on participants’ demographic and social characteristics, drug use characteristics,
drug market access patterns, health and social functioning, and health service utilisation. Participants are followed-
up on an annual basis.
Results: 688 PWID were recruited into the study. At baseline, the median age of participants was 27.6 years (IQR:
24.4 years – 29.6 years) and two-thirds (67%) were male. Participants reported injecting for a median of 10.2 years
(range: 1.5 months – 21.2 years), with 11% having injected for three years or less. Limited education,
unemployment and previous incarceration were common. The majority of participants (82%) reported recent heroin
injection, and one third reported being enrolled in Opioid Substitution Therapy (OST) at recruitment. At 12 months
follow-up 458 participants (71% of eligible participants) were retained in the study. There were few differences in
demographic and drug-use characteristics of those lost to follow-up compared with those retained in the study,
with attrition significantly associated with recruitment at an inner-urban location, male gender, and providing
incomplete contact information at baseline.
Conclusions: Our efforts to recruit a sample of largely out-of-treatment PWID were limited by drug market
characteristics at the time, where fluctuating heroin availability has led to large numbers of PWID accessing low-
threshold OST. Nevertheless, this study of Australian injectors will provide valuable data on the natural history of
drug use, along with risk and protective factors for adverse health outcomes associated with injecting drug use.
Comprehensive follow-up procedures have led to good participant retention and limited attrition bias.
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People who inject drugs (PWID) are exposed to blood-
borne virus (BBV) infections [1,2], injecting-related in-
juries [3,4] and risk of overdose [5-7], and experience
greater levels of both physical and mental impairment
compared with the general population [8-14]. Meta-
analysis of cohort studies has shown that PWID have a
greatly increased risk of premature death, attributable to
both AIDS and non AIDS-related causes [15], with mor-
tality among opiate injectors estimated to be approxi-
mately 19 times higher than the general population [16].
Additionally, injecting drug use is associated with a
range of social and economic harms [17-21].
Our ability to respond to the significant morbidity and
mortality associated with injecting drug use is limited by
our lack of understanding of the complex ways in which
drug-related harms are produced, and the ways in which
interventional efforts can be optimised. Most Australian
and much international research among this population
has been cross-sectional, which captures only a single
time point and cannot explore how patterns of risk be-
haviour, and subsequent health outcomes may change
during a person’s injecting career.
Cohort studies provide a unique opportunity to meas-
ure changes in behavior and disease transmission over
time. They can, however, be difficult studies to conduct;
they require sufficient funding to facilitate follow-up
over time [22], and are subject to cohort effects, as well
as selection bias if they experience high levels of attri-
tion, particularly if loss to follow-up is associated with
important participant characteristics [23,24]. Addition-
ally, controlling for confounding when assessing rela-
tionships between behaviour and disease transmission
can prove challenging [25,26].
Cohort studies involving PWID have proven especially
difficult; although studies have achieved follow-up rates
of 68-80%, attrition is often associated with factors such
as homelessness, incarceration and early death [27-33].
While a number of successful PWID cohorts are ongoing
in the USA and Canada, in Australia such studies have
been relatively rare. In Australia, longitudinal studies
among PWID have been conducted among in-treatment
samples [34], which comprise mainly long-term injectors
who are either injecting infrequently or not at all, and thus
may not provide accurate information about the preva-
lence and incidence of risk behaviour and disease. When
community-based cohorts have been conducted, they have
been limited by short duration of follow-up [35,36]. Out-
comes measured in these studies have primarily focused
on either hepatitis C incidence or drug treatment out-
comes, with limited data collected on health outcomes
more broadly [34-37]. Further, most studies involving
PWID in Australia are generally focused on an older sam-
ple of PWID who initiated and became entrenched ininjecting drug use in the mid-late 1990s, a period that was
characterised by the ready availability of heroin [38] -
markedly different to the drug market characteristics of
today. It is not clear whether patterns of drug use and re-
lated risk behaviour among this older cohort is reflective
of newer, younger injectors. For these reasons, we need
long-term studies of Australian PWID that include those
people who have commenced injecting more recently and
continue to regularly inject drugs in contemporary drug
market conditions.
The Melbourne Injecting Drug User Cohort Study
(MIX) was designed to explore the natural history of
injecting drug use, as well as to identify risk and protect-
ive factors for adverse health outcomes and health
service utilisation among PWID. We aimed to recruit a
large sample of young, out-of-treatment PWID, with
equal numbers preferring heroin or methamphetamine
as their drug of choice. In this paper we report on
methods used to recruit and retain MIX participants, de-
scribe the cohort’s baseline characteristics, and explore
factors associated with attrition at 12 months follow-up.
Methods
Setting
The study was conducted in Melbourne, the second lar-
gest city in Australia (population ~4 million (2009)) and
capital city of the state of Victoria [39]. Baseline recruit-
ment was conducted between November 2008 and March
2010, across one outer-urban and two inner-urban
(Inner-West and Central) areas of Melbourne where illicit
drug markets had been identified through previous studies
and/or where primary needle and syringe exchange
programs (NSPs) were located (Figure 1).
Eligibility criteria
Individuals were eligible for the study if they: (1) reported
being aged between 18 and 30 years old; (2) had injected
either heroin or methamphetamine at least six times over
the previous six months; (3) were currently residing in
Melbourne; (4) were willing to provide detailed contact in-
formation including their full name, residential address
and telephone number; and (5) were able and willing to
provide a valid Medicare card number, to be used, along
with other personal details, for data linkage (Medicare is
Australia’s universal health-care system which provides ac-
cess to free or subsidised medical and allied health ser-
vices; the Medicare number is unique for each individual
listed on the system).
A sixth criterion, ‘not currently being prescribed Opi-
oid Substitution Therapy (OST)’ was withdrawn three
months into the study due to the high number of other-
wise eligible participants who were being excluded (only
31 participants were enrolled into the study during this
time). This decision was made in light of the drug market
Figure 1 Geographic location of recruitment sites, and distribution of participants by postcode of residence at baseline.
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oin availability and purity led to ever-increasing numbers
of PWID accessing low-threshold OST and cycling in and
out of treatment regularly [38,40,41].
Amendments were also made to the selection criterion
regarding age, as it came to light that the PWID popula-
tion in Melbourne is ageing, while uptake of injection is
decreasing [42], making it difficult to recruit younger
PWID. As such PWID who were slightly older than the
target age range, but were not on OST, were also in-
cluded in the study. The financial and time constraints
of the longitudinal study design were also a factor in
these decisions.Pilot interviews
Thirty-two pilot interviews were conducted between
March and August 2008 to identify any ambiguities or
other problems within the questionnaire. Pilot partici-
pants were PWID who were previously known to re-
searchers, and who met the study eligibility criteria. Pilot
interviews are not reported separately to baseline data in
this report.Recruitment strategies
Participants were recruited using Respondent Driven
Sampling (RDS), street outreach and snowball sampling,
in order to maximise the number and diversity of partic-
ipants recruited over a limited time period [43].Respondent driven sampling
RDS is a modified chain-referral sampling technique
used for the recruitment of hard-to-reach populations
[44]. A small number of ‘seed’ participants are selected
from the chosen population, and monetary incentives
are used to facilitate recruitment of additional partici-
pants through seeds’ social networks. Weighted analysis
based on social network sizes is conducted to adjust for
the bias that is generally associated with chain-referral
methods [44,45].
Up to five PWID from each recruitment site who were
known to study researchers through participation in pre-
vious studies or through agency referral, and met the
study eligibility criteria, acted as the seeds. Following
interview, each seed received a set of uniquely numbered
recruitment coupons and was invited to recruit a max-
imum of three peers into the study. The coupons di-
rected interested parties to contact researchers via a
free-call telephone number, in order to be screened for
study eligibility. Once eligibility was confirmed, an ap-
pointment time was made to conduct the interview.
Additional seeds were added as required to boost re-
cruitment (on an ad hoc basis).
Street outreach and snowball sampling
A team of researchers regularly attended each of the re-
cruitment locations. Eligible participants were recruited
through word of mouth and flyers posted in relevant com-
munity agencies. PWID who met the eligibility criteria
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previous studies were also actively recruited. These partic-
ipants were then given the opportunity to invite their con-
tacts to also participate in the study. Participants recruited
through street outreach and snowball sampling also re-
ceived RDS coupons to distribute to their peers. All partic-
ipants who returned an RDS coupon are considered as
having been recruited through the RDS arm of the study.Questionnaire design and administration
Interviewer-administered questionnaires were conducted
using hand-held personal digital assistants (PDAs). In-
formation was entered into a database constructed using
Questionnaire Design System Versions 2.4-2.6 (NOVA
Research Company, Maryland, USA).
To protect participant confidentiality, contact details
and survey data were entered into two separate data-
bases. Detailed contact information was recorded to en-
hance the likelihood of successful follow-up, including
the participant’s full name, date of birth, alias or street
name, residential address, land and mobile telephone
numbers, and contact details for a nominated friend or
relative who was likely to know the participant’s where-
abouts during the study. Medicare number and RDS
coupon details were also recorded in this database. A
unique identifier was assigned to each participant using
an algorithm based on the participant’s first name, sur-
name and year of birth.
The study questionnaire covered four domains: demo-
graphic and social characteristics; drug use characteris-
tics and drug market access; health and social
functioning; and health service utilisation. Standardised
and validated questionnaire items were used where ap-
propriate. Details of selected variables collected are
outlined in Table 1.
Eligibility screening and interviews were conducted
on-site either in a public space (e.g. park, outdoor cafe)
or in a mobile study van, with interviews taking 39 mi-
nutes on average to complete (SD: 18 minutes). Partici-
pants were reimbursed AU$30 (US$19.83 in November
2008) for their time and out-of-pocket expenses in ac-
cordance with accepted practice [46], and an additional
AU$10 for each coupon returned which resulted in an
eligible interview.Follow-up procedures
Ideally, participants will be followed up annually for a
minimum of four years (incorporating completion of
a structured interview, as well as the collection of a
blood sample for BBV testing). Given the anticipated
difficulty in retaining participants we employed a var-
iety of strategies to maintain contact with participants
between interviews.In addition to the extensive contact information col-
lected at baseline, participants received a follow-up card
noting the approximate date of their next interview and
listing a free-call telephone number to contact re-
searchers and update their details as required. Field-
based researchers maintained contact with participants
they encountered in the field, and updated contact de-
tails when possible.
Two to four weeks prior to their scheduled follow-up
date researchers attempted to contact participants, ini-
tially via telephone (using both voice calling and text
messaging). If telephone contact was unsuccessful re-
searchers posted a letter to the participant’s home ad-
dress or attempted contact through their nominated
friend or relative. Field-based researchers actively sought
out participants who were due for follow-up, and sys-
tematically recorded information received through their
networks about a participant’s whereabouts (e.g. if they
had been incarcerated). Telephone interviews were
conducted with participants who were no longer resid-
ing in Melbourne if valid contact details were available.
In order to maximise the number of participants com-
pleting each follow-up interview, interviews could be
conducted up to two months prior to the scheduled
follow-up date if opportunistic contact was made. There
was no end-point at which participants became ineligible
to complete an interview, however, to avoid overlap in
referent time periods, at least six months must have
elapsed between interviews.
The follow-up interview was conducted using the
same procedures as the baseline interview, with minor
changes to the questionnaire to reduce repetition and in-
corporate prospectively occurring events. Participants
were again reimbursed AU$30 per interview. Receipt of
further study funding facilitated the collection of venous
blood samples, to be tested for HIV, hepatitis B and hepa-
titis C infection. Participants who agree to provide a blood
sample at each follow-up interview receive an additional
AU$10 for the extra time and inconvenience involved.
Staff training
Study staff received extensive training in field-based data
collection, including the use of PDAs, administration of
the questionnaire and adherence to standard operating
procedures for field-based researchers, as well as com-
pleting accredited training courses in phlebotomy and
BBV pre-and-post-test counselling.
Ethics approval
The study was approved by the Victorian Department of
Human Services (now Department of Health) and Monash
University Human Research Ethics Committees. Written
informed consent, including consent to access Medicare
information, was obtained from all participants.
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We conducted analyses to explore variations in partici-
pant socio-demographic characteristics, patterns of drug
use and health status by recruitment site using the chi-
square test for categorical variables, Wilcoxon rank-sum
test for non-parametric continuous variables and the
Kruskal-Wallis test for non-parametric continuous vari-
ables across more than two groups. Multivariable logistic
regression was conducted to identify independent corre-
lates of attrition at 12-months follow-up. Analyses were
conducted using Stata Version 11.1 (Statacorp LP, Texas,
USA), with a significance level of p<0.05. Missing data
are not reported.
This manuscript has been prepared in accordance with
the Strengthening the Reporting of Observational Stud-
ies in Epidemiology (STROBE) Statement [47].
Results
Baseline characteristics
Six hundred and ninety-four PWID were recruited into
the study, but due to a technical error, baseline data for
six participants were lost, resulting in a final sample of
688 participants. The median age of participants was
27.6 years (IQR: 24.4 years – 29.6 years). Participants
were predominantly male (67%) and had been injecting
drugs for a median of 10.2 years (range: 1.5 months –
21.2 years), with 11% of participants reporting injecting
for three years or less (n=76). The majority of partici-
pants had not completed high school (80%), were un-
employed (86%) and were dependent on government
benefits as their main source of income (86%). One
hundred and thirty-one participants (19%) reported be-
ing homeless or living in unstable accommodation such
as boarding houses at the time of interview. The vast
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the month prior to recruitment (82%, n=563). Of the
remaining participants, 27% reported only recent am-
phetamine injection (n=34), 48% reported injecting
neither heroin nor amphetamine but other drugs, pre-
dominantly pharmaceutical opiates (n=60) and 25% had
abstained from drug injection in the past month (n=31).
One third of participants (35%) were prescribed OST at
the time of interview, with those out-of-treatment sig-
nificantly younger (median age: 27.3 years vs. 28.2 years;
p=0.025), than those in treatment.
One third of participants were recruited through RDS
(36%, n=246), with RDS-recruited participants generally
similar to those recruited through street outreach and
snowball sampling. Fifty-three per cent of participants
(n=361) were recruited from Melbourne’s Inner West,
26% from Central Melbourne (n=177), and 22% from
the Outer-urban site (n=150). Participants generally re-
sided in close proximity to recruitment sites (Figure 1). Sig-
nificant differences were detected in socio-demographic
and drug use characteristics of participants across recruit-
ment sites (Table 2). Participants from the Inner-West and
Central sites were less likely to be born in Australia com-
pared with those from the outer-urban site (76% and 77%,
respectively vs. 93%), reflecting the significant South-East
Asian and Horn of Africa migrant communities in these
areas. Patterns of substance use varied across sites, with
40% of participants from each of the inner-urban sites
reporting abstaining from alcohol consumption in the past
month, compared with 23% of participants from the outer-
urban site. Participants from the outer-urban site com-
menced injecting at a median age of 16 years (IQR: 14–18),
slightly younger than other participants (median: 17, IQR:
15–20 in Inner-West, and 17, IQR: 15–19 in Central), and
were significantly less likely to report heroin as their first
drug injected (52% vs. 72% and 60% in Inner-West and
Central respectively). At baseline, a smaller proportion of
outer-urban participants reported recent heroin injection
compared with those from other areas (50% vs. 94%
(Inner-West) and 86% (Central)), with 11% injecting am-
phetamines only, and 32% injecting other drugs only.
Frequency of recent heroin injection was lowest in the
outer-urban site, where a greater proportion of participants
reported being on OST at baseline (48% vs. 34% in Inner-
West and 28% in Central). Patterns of recent attendance at
PWID-specific primary health care (PHC) services, general
practice (GP) clinics and hospital outpatient clinics were
also significantly different across recruitment sites.
Retention at twelve months follow-up
At twelve months follow-up, 30 participants (4%) were
known to be incarcerated, to have died or to no longer
be residing in Australia, and an additional 10 partici-
pants (1%) voluntarily withdrew from the study. Of theparticipants who were eligible for follow-up, 458 (71%)
were retained in the study (Figure 2), and completed
follow-up interviews a median of 357 days post-baseline
(IQR: 317–435 days).
The baseline characteristics of participants who com-
pleted a 12-month follow-up interview were compared
with those who did not. Independent correlates of
attrition were: recruitment from Inner West or Central
Melbourne, male gender, and failing to provide a telephone
number or residential address at baseline (Table 3).
Discussion
The MIX cohort constitutes the largest Australian
community-based PWID cohort to-date, and differs from
other Australian PWID cohorts in several important ways.
Firstly, our cohort is recruited from the community,
and includes a large sample of out-of-treatment PWID;
just over one third of our participants were prescribed
OST at recruitment, compared with 51%-63% of street-
based PWID and NSP-attendees interviewed in recent
Victorian drug trend monitoring studies [48-50]. As
such, it does not possess the selection effects associated
with recruitment from a particular place, such as treat-
ment facilities. Although PWID who regularly attend
primary care centres or pharmacies to obtain pharmaco-
therapy treatment may be easier to retain in longitudinal
studies, PWID in-treatment tend to be different to those
out-of-treatment, commonly being older and further
progressed in their injecting careers [34,40]. At the time
of recruitment, the heroin market in Melbourne had
been relatively depressed for some time [38,51], and re-
search suggests that this reduction in heroin supply was
associated with both reduced heroin injection among
current injectors and reduced initiation into injecting
[42,52]. This decreased the pool of newer, out-of-treat-
ment PWID, preventing us from recruiting as large a
sample of these users as hoped. Despite this, our cohort
will still provide vital information about transitions into
and out of drug treatment and the factors which motiv-
ate these decisions. Further, the inclusion of individuals
both in and out of treatment will allow for assessments
of a range of barriers to treatment as well as evaluations
of the impact of treatment.
Participants in our cohort were recruited from three
locations across Melbourne, where illicit drug markets
and/or NSPs are located, with significant differences in
socio-demographic and drug use patterns detected across
sites. The Inner-West and Central areas are historically
working-class and industrial; today, they include large
public housing estates, and are home to significant Asian
migrant populations, and more recently, refugee popula-
tions from the Horn of Africa [53-55]. Following a transi-
tion from predominantly private dealing, street-based
heroin markets emerged in these areas in the mid-1990s
Table 2 Socio-demographic, drug use and health characteristics at baseline, by recruitment location
Variable Recruitment location
χ2Inner-West Central Outer-urban
N=361 N=177 N=150 p-value
n (%) n (%) n (%)
Recruitment method
0.615RDS 130 (36) 67 (38) 49 (33)
Other 231 (64) 110 (62) 101 (67)
Demographic and social characteristics
Sex
0.920Female 119 (33) 58 (33) 52 (35)
Male 242 (67) 119 (67) 98 (65)
Age
Median (IQR) 27.4 (24.4-29.3) 28.0 (24.4-29.8) 27.8 (23.9-29.6) 0.579
Aboriginal/Torres Strait Islander status
0.534Yes 22 (6) 12 (7) 6 (4)
No 339 (94) 165 (93) 144 (96)
Country of birth
<0.001Australia 275 (76) 136 (77) 139 (93)
Other 84 (24) 40 (23) 11 (7)
Main income source (last month)
0.140
Wage or salary 28 (8) 15 (9) 15 (10)
Government pension or benefits 308 (85) 150 (85) 131 (89)
Other1 25 (7) 11 (6) 2 (1)
Employment status
0.547Not employed 311 (86) 154 (87) 125 (83)
Employed 50 (14) 22 (13) 25 (17)
Education
0.055
Did not complete year 10 118 (33) 49 (28) 64 (43)
Completed year 10–11 169 (47) 85 (48) 63 (42)
Completed high school or higher 74 (21) 43 (24) 23 (15)
Current accommodation type
<0.001
Owner-occupied 97 (27) 27 (15) 30 (20)
Private rental 103 (29) 41 (24) 48 (32)
Public housing 104 (29) 54 (30) 49 (33)
No stable accommodation 55 (15) 55 (31) 21 (14)
Incarceration history
0.150
Never been in prison 145 (40) 76 (43) 55 (37)
Incarcerated once 123 (34) 46 (26) 42 (28)
Incarcerated two or more times 92 (26) 54 (31) 51 (35)
Recent arrest (last 12 months)
0.299Yes 201 (56) 86 (49) 82 (56)
No 159 (44) 89 (51) 64 (44)
Drug use characteristics
Age at first injection
<0.001
Median (IQR) 17 (15–20) 17 (15–19) 16 (14–18)
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Table 2 Socio-demographic, drug use and health characteristics at baseline, by recruitment location (Continued)
Duration of injecting career (years)
0.004
Median (range) 9.7 (<1-20.5) 10.2 (<1-21.2) 11.3 (1.1-21.2)
First drug injected 261 (72) 106 (60) 78 (52)
<0.001
Heroin 91 (25) 63 (36) 59 (39)
Amphetamines 4 (1) 5 (3) 1 (1)
Other stimulant 3 (1) 2 (1) 10 (7)
Other opiate 2 (1) 1 (1) 2 (1)
Other
Drugs injected last month
<0.001
Heroin only 172 (48) 85 (48) 22 (15)
Heroin and other drugs 165 (46) 67 (38) 52 (35)
Amphetamines only 9 (3) 8 (5) 17 (11)
Other drugs only2 4 (1) 8 (5) 48 (32)
Did not inject in last week 11 (3) 9 (5) 11 (7)
Frequency of heroin injection (last week)
0.022
Median (range) 5 (1–60) 4 (1–50) 3 (1–28)
Frequency of methamphetamine injection
(last week) 0.047
Median (range) 2 (1–25) 2 (1–42) 2 (1–28)
Ever been on OST 0.072
Yes 260 (72) 115 (65) 114 (77)
No 99 (28) 61 (35) 35 (23)
Currently on OST 0.001
Yes 121 (34) 50 (28) 71 (48)
No 238 (66) 126 (72) 78 (52)
Frequency of alcohol use (last month)
0.001
Never 146 (40) 69 (39) 34 (23)
Once per week or less 119 (33) 48 (27) 51 (34)
Two to three times per week 31 (9) 20 (11) 26 (18)
Four or more times per week 65 (18) 39 (22) 38 (26)
Heroin overdose (lifetime)
0.654Yes 141 (39) 68 (39) 64 (43)
No 219 (61) 107 (61) 84 (57)
Heroin overdose (last six months)
0.799Yes 36 (26) 18 (27) 14 (22)
No 104 (74) 50 (74) 50 (78)
Health characteristics
BBV status (self-reported)3 n=324 n=162 n=143
HCV positive 164 (51) 80 (49) 64 (45) 0.863
Number of health services used (last month) n=352 n=172 n=148
Median (range) 1 (0–7) 1 (0–9) 1 (0–5) 0.013
Health services used (last month)4
Hospital Emergency Department 47 (13) 22 (12) 24 (16) 0.593
Hospital Inpatients 14 (4) 10 (6) 11 (7) 0.260
Hospital Outpatients 10 (3) 15 (9) 8 (5) 0.012
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Table 2 Socio-demographic, drug use and health characteristics at baseline, by recruitment location (Continued)
General Practice 200 (56) 95 (54) 105 (71) 0.003
PWID Primary Health Care Centre 55 (15) 41 (23) 22 (15) 0.047
Ambulance 25 (7) 15 (9) 14 (9) 0.620
Psychologist/psychiatrist 45 (13) 30 (17) 22 (15) 0.362
Other5 45 (13) 33 (19) 22 (15) 0.165
1 Includes criminal activity, sex work, being supported by spouse or family member, no current income.
2 Includes cocaine, ecstasy, pharmaceutical stimulants, benzodiazepines, Unisom and participants who reported >1 drug injected most often.
3 Among those who reported ever being tested for HCV.
4 Among participants who completed question (n=675 - 684); Not mutually exclusive.
5 Includes specialist physician, dentist, allied health service.
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[38,53,56]. In contrast, the outer-urban recruitment site
is home to a predominantly Anglo-Australian commu-
nity, with manufacturing and construction the main in-
dustries [57,58]; MIX study participants from this site
displayed a preference for amphetamine and pharma-
ceutical opiate injection, presumably reflecting limited
access to heroin due to geographic distance from active
heroin markets. Differences in patterns of alcohol con-
sumption were also recorded across research sites and
may reflect a number of factors including neighbour-
hood liquor outlet density [59] and differing cultural at-
titudes towards alcohol consumption. The role of the
geographical environment in drug use and associated
risks and harms warrants further investigation, and will
be examined in future.
Rather than focusing specifically on BBV incidence or
drug treatment outcomes – the main focus of previousFigure 2 Participant flow diagram.cohorts of Australian PWID [34-37] - our study collects
data on a broad range of other health outcomes, includ-
ing patterns of drug injection and injecting cessation,
physical and mental health, and engagement with health
services. Of particular interest is the fact that although
58% of participants reported attending a GP clinic in the
past month, just 17% reported recent attendance at one
of the five state-funded free PWID-specific PHC clinics,
despite these clinics generally being located reasonably
close to participants’ residences. Further analysis is re-
quired to explore the characteristics of clients attending
these services and their presenting complaints, and to
understand the ways in which patterns of health service
utilisation are associated with factors such as recruit-
ment site, service availability and patterns of drug use.
The use of prospective data will also enable examination
of longer-term drug use and other health outcomes
among PWID attending these services.
Table 3 Correlates of attrition at 12-months
Variable Followed-up Not followed-up Univariate Multivariable
N=458 N=230 OR (95% CI) OR (95% CI)
n (%) n (%)
Recruitment method
RDS 164 (36) 82 (36) 1
Other 294 (64) 148 (64) 1.00 (0.72-1.40)
Recruitment location
Inner West 230 (50) 131 (57) 2.02 (1.30-3.14)** 2.10 (1.33-3.32)**
Central 111 (24) 66 (29) 2.11 (1.29-3.45)** 1.80 (1.25-2.60)**
Outer-Urban 117 (26) 33 (14) 1 1
Sex
Male 285 (62) 174 (76) 1 1
Female 173 (38) 56 (24) 0.53 (0.37-0.76)** 0.56 (0.38-0.80)**
Age
Median (IQR) 27.8 (24.1-29.7) 27.3 (24.6-29.4) 0.98 (0.94-1.03)
Aboriginal/Torres Strait Islander status
Yes 25 (6) 15 (7) 1
No 433 (95) 215 (94) 1.21 (0.62-2.34)
Country of birth
Australia 373 (82) 177 (78) 1
Other 84 (18) 51 (22) 0.78 (0.53-1.16)
Main income source (last month)
Wage or salary 36 (8) 22 (10) 1
Government pension or benefits 392 (86) 197 (86) 0.82 (0.47-1.44)
Other1 28 (6) 10 (4) 0.58 (0.24-1.43)
Employment status
Not employed 391 (86) 199 (87) 1
Employed 66 (14) 31 (13) 0.92 (0.58-1.46)
Education
Did not complete year 10 139 (31) 91 (40) 1
Completed year 10–11 223 (49) 94 (41) 0.64 (0.45-0.92)*
Completed high school or higher 94 (21) 45 (20) 0.73 (0.47-1.14)
Current accommodation type
Owner-occupied 104 (23) 50 (22) 1
Private rental 115 (25) 77 (34) 1.39 (0.89-2.17)
Public housing 146 (32) 61 (27) 0.87 (0.55-1.36)
No stable accommodation 90 (20) 41 (18) 0.95 (0.57-1.56)
Incarceration history
Never been in prison 194 (43) 82 (36) 1
Incarcerated once 136 (30) 75 (33) 1.30 (0.89-1.91)
Incarcerated two or more times 126 (28) 71 (31) 1.33 (0.90-1.97)
Recent arrest (last 12 months)
Yes 236 (52) 133 (59) 1
No 218 (48) 94 (41) 0.77 (0.55-1.06)
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Table 3 Correlates of attrition at 12-months (Continued)
Age at first injection
Median (range) 17 (11–32) 17 (8–29) 0.99 (0.94-1.03)
Duration of injecting career (years)
Median (range) 10.0 (<1-20.8) 10.3 (<1-21.2) 1.00 (0.96-1.03)
Ever been on OST
Yes 335 (73) 154 (68) 1
No 121 (27) 74 (32) 1.33 (0.94-1.88)
Currently on OST
Yes 175 (38) 67 (29) 1
No 281 (62) 161 (71) 1.50 (1.06-2.11)*
Drugs injected last month
Heroin only 187 (41) 92 (40) 1
Heroin and other drugs 183 (40) 101 (44) 1.11 (0.53-2.34)
Amphetamines only 22 (5) 12 (5) 1.47 (0.69-3.13)
Other drugs only 48 (11) 12 (5) 0.51 (0.26-1.00)
Did not inject last month 18 (4) 13 (6) 1.12 (0.79-1.59)
Telephone number provided
at baseline
Yes 440 (96) 195 (85) 1 1
No 18 (4) 35 (15) 4.39 (2.42-7.94)** 2.90 (1.53-5.48)**
Home address provided at baseline
Yes 454 (99) 212 (92) 1 1
No 4 (1) 18 (8) 9.64 (3.22-28.82)** 6.58 (2.05-21.08)**
* p<0.05, **p<0.01; Hosmer-Lemeshow test: p=0.96.
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snowballing and street outreach to ensure that a diverse
sample of PWID were included in the study, there were
few significant differences across recruitment arms.
While not the focus of this paper, further analysis, in-
cluding the calculation of RDS-weighted population
prevalence estimates, will facilitate better understanding
of the usefulness of this recruitment strategy.
Despite having worked in these field sites for a number
of years [60,61], and conducting formative research prior
to study commencement (field-based observations and
pilot interviews), the Melbourne drug market is dynamic,
and unanticipated changes in both people accessing the
market, and availability of different drug types did occur
[62,63]. In response, a number of changes to the eligibility
criteria of the study, as well as study procedures were
implemented.
Firstly, we relaxed our age restriction on eligibility,
which resulted in the inclusion of 95 participants aged
30–31, and 38 participants aged over 31 in the study. As
such our sample is slightly older than initially hoped,
with a median age of 27.6 years, making them slightly
younger than participants in the Victorian cohort recruited
by Crofts et al. in the early 1990s [37], but older thancohorts recruited in Sydney and Melbourne in the mid-
2000s [35,36]. It has been noted that PWID in this juris-
diction are an ageing population; repeat cross-sectional
surveys have indicated that the median age of NSP at-
tendees in Victoria has increased significantly from 26
years in 1997 to 35 years in 2010 [50]. Similar increases
in mean ages have been observed among PWID survey
participants in Victoria’s illicit drug trends monitoring
system over the past ten years [48,64]. This is likely to
be due to the population of ageing PWID who initiated
injecting in the 1980s and 1990s and continue to inject
today, combined with decreasing numbers of young
people initiating injection [42]. The median year of
injecting initiation among our sample, however, was
1999 (IQR: 1996–2003), with a median delay of one year
to regular injecting drug use. Thus, while a proportion
of participants initiated injecting during the latter years
of the heroin ‘glut’ [38], there are few participants in our
study for whom drug use was already entrenched during
this period, with the majority commencing regular
injecting in the setting of limited heroin availability.
Our study initially aimed to recruit both primary her-
oin and methamphetamine injectors, as most previous
Australia cohorts have been comprised mostly of heroin
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creases in crystal methamphetamine use, relatively little
was known about patterns of methamphetamine injec-
tion. By the time study recruitment commenced how-
ever, recent reports of crystal methamphetamine use had
again decreased [66], meaning that only a small number
of primary methamphetamine injectors met the study
eligibility criteria. Nonetheless, prospective data collec-
tion will enable ongoing monitoring of trends in meth-
amphetamine use, and provide opportunities to explore
potential changes in drug use and health outcomes as
participants transition between different patterns of pri-
mary heroin and methamphetamine use.
While other Australian PWID cohorts have been lim-
ited by short durations of follow-up, the MIX cohort will
be followed up annually for a minimum of four years
(with funding for further follow-up to be sought). At 12-
months’ follow-up, the retention rate was 71%, compar-
able to similar international studies, which had follow-up
rates from 68%-83% reported over durations ranging from
three months to four years [27-30,32]. Similar to other
longitudinal studies of vulnerable populations, we found
that the collection of detailed contact information at base-
line, comprehensive follow-up procedures and an ongoing
field presence that allowed researchers to build familiarity
and trust with participants, were all integral in tracking
respondents [67,68]; participants who did not provide
complete contact details at baseline were more likely to be
lost to follow-up. Importantly, while attrition was associ-
ated with male gender, those lost to follow-up were other-
wise similar to participants retained in the study, thus
limiting the impact of attrition bias on our findings. The
long duration of follow-up, combined with future data
linkage through administrative data (e.g. the Medicare
system) beyond the period of face-to-face follow-up will
produce rich and versatile data enabling a better under-
standing of the natural history of injecting drug use and
patterns of morbidity and mortality (overall, as well as
among particular subgroups of PWID). These data will
be integral to the evaluation of health and social inter-
ventions among this group.
Limitations
Due to ethical considerations, we were not permitted to
recruit participants younger than 18 years of age, how-
ever due to a miscommunication a small number of
participants aged 16 and 17 were inadvertently recruited
into the study; ethics approval has been obtained to use
data from these participants. It remains unclear whether
this population of adolescent PWID are being targeted
effectively by research or health interventions.
Given the complexities involved with street-based re-
cruitment across multiple field sites, involving a large re-
search team, it was not possible to monitor how manyPWID were invited but declined to participate in the
study. Unwillingness to consent to the provision of Medi-
care information may have been associated with declining
to participate in the study.
As with much PWID research, our data may be lim-
ited by selection bias, and as behavioural data were self-
reported, also by recall and social acceptability bias.
Future data linkage and BBV testing will enable us to as-
sess the accuracy of some self-reported variables.Conclusions
Although PWID can be difficult to retain in longitudinal
studies, well-planned follow-up procedures and an on-
going field presence can lead to high levels of retention
and minimal attrition bias. Data from the MIX cohort
will allow for the exploration of the natural history of
injecting drug use, and the identification of both risk
and protective factors for adverse health outcomes asso-
ciated with injecting drug use in Australia.
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